Dysregulation of histone deacetylases in ocular diseases
Arch Pharm Res. 2023 Dec 27. doi: 10.1007/s12272-023-01482-x. Online ahead of print.ABSTRACTOcular diseases are a growing global concern and have a significant impact on the quality of life. Cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy are the most prevalent ocular diseases. Their prevalence and the global market size are also increasing. However, the available pharmacotherapy is currently limited. These diseases share common pathophysiological features, including neovascularization, inflammation, and/or neurodegeneration. Histone deacetylases (HDACs) are a class of enzymes that catalyze ...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Jae Hyun Jun Jun-Sik Kim Leon F Palomera Dong-Gyu Jo Source Type: research
Gastric cancer and mesenchymal stem cell-derived exosomes: from pro-tumorigenic effects to anti-cancer vehicles
Arch Pharm Res. 2023 Dec 27. doi: 10.1007/s12272-023-01477-8. Online ahead of print.ABSTRACTGastric cancer (GC) is one of the most prevalent malignancies in the world, with a high mortality rate in both women and men. Conventional treatments, like chemotherapy, radiotherapy and surgery, are facing some drawbacks like acquired drug resistance and various side effects, leading to cancer recurrence and increased morbidity; thus, development of novel approaches in targeted therapy would be very beneficial. Exosomes, extracellular vesicles with a size distribution of sub-150 nm, interplay in physiological and pathophysiological...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Maryam Dolatshahi Ahmad Reza Bahrami Qaiser Iftikhar Sheikh Mohsen Ghanbari Maryam M Matin Source Type: research
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
In this study, we aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of pantoprazole in populations with various CYP2C19 metabolic activities. A comprehensive investigation of previous reports and drug databases was conducted to collect the clinical pharmacogenomic data, physicochemical data, and disposition properties of pantoprazole, and the collected data were used for model establishment. The model was evaluated by comparing the predicted plasma concentration-time profiles and/or pharmacokinetic parameters (AUC and Cmax) with the clinical observation results. The p...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Eunvin Ko Ju Yeon Mo Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date
Arch Pharm Res. 2023 Dec 26. doi: 10.1007/s12272-023-01481-y. Online ahead of print.ABSTRACTArsenical medicine has obtained its status in traditional Chinese medicine for more than 2,000 years. In the 1970s, arsenic trioxide was identified to have high efficacy and potency for the treatment of acute promyelocytic leukemia, which promoted many studies on the therapeutic effects of arsenic trioxide. Currently, arsenic trioxide is widely used to treat acute promyelocytic leukemia and various solid tumors through various mechanisms of action in clinical practice; however, it is accompanied by a series of adverse reactions, esp...
Source: Archives of Pharmacal Research - December 26, 2023 Category: Drugs & Pharmacology Authors: Meng Yan Hao Wang Rui Wei Wenwen Li Source Type: research
The PIN1-YTHDF1 axis promotes breast tumorigenesis via the m < sup > 6 < /sup > A-dependent stabilization of AURKA mRNA
In conclusion, the findings of our study suggest that increased YTHDF1 stability induced by PIN1 promotes breast tumorigenesis via the stabilization of AURKA mRNA. Targeting the PIN1/YTHDF1 axis may represent a novel therapeutic strategy for breast cancer.PMID:38147203 | DOI:10.1007/s12272-023-01480-z (Source: Archives of Pharmacal Research)
Source: Archives of Pharmacal Research - December 26, 2023 Category: Drugs & Pharmacology Authors: Pratikshya Shrestha Garam Kim Hyelim Kang Poshan Yugal Bhattarai Hong Seok Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
